64214-66-0

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-N-Methoxy-N-MethylbutyraMide is used as a pharmaceutical intermediate for its integral role in the synthesis of a range of drugs. Its chemical structure and properties make it a valuable component in the development of new medicinal compounds, enhancing the therapeutic potential of pharmaceutical products.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-Chloro-N-Methoxy-N-MethylbutyraMide serves as a key building block, facilitating the creation of novel drug candidates. Its unique characteristics contribute to the advancement of drug discovery, potentially leading to the development of more effective treatments for various health conditions.
Used in Drug Discovery:
4-Chloro-N-Methoxy-N-MethylbutyraMide is utilized in drug discovery processes to explore its potential in forming new pharmaceutical agents. Its inclusion in these processes is vital for identifying and optimizing compounds that can address unmet medical needs and improve patient outcomes.

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 4635-59-0 4-Chlorobutanoyl chloride 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 7623-11-2 2-chlorobutyryl chloride 
• 3153-37-5 methyl 4-chlorobutyrate 
• 3153-36-4 4-chloro-butyric acid ethyl ester 

Downstream Products

• 138344-14-6 [2-(5-Chloro-2-oxo-pentyl)-4-methoxy-phenyl]-carbamic acid tert-butyl ester 
• 5891-21-4 5-chloro-2-pentanone 
• 150668-36-3 4-chloro-1-(3,5-dimethylphenyl)butan-1-one 
• 40877-17-6 4-chloro-1-(2-methoxyphenyl)-1-butanone 
• 1246385-18-1 C₁₇H₁₄ClFN₂O 
• 258882-48-3 4-chloro-1-(3-methoxyphenyl)-1-butanone 
• 43076-59-1 4-chloro-1-(thien-2-yl)-1-butanone 
• 939-52-6 4-chloro-1-phenylbutan-1-one 
• 40877-19-8 4-chloro-1-(4-methoxyphenyl)butan-1-one 
• 1216260-42-2 4‐chloro‐1‐(2,5-difluorophenyl)butan-1-one 
• 38425-26-2 4-chloro-1-(4-methylphenyl)butan-1-one 
• 80086-24-4 6-chloro-1-phenylhexan-3-one 

Relevant academic research and scientific papers

Development of a tandem cyclization mediated by samarium(II) iodide: sequential intramolecular conjugate addition/nucleophilic acyl substitution

The development of a one-pot tandem intramolecular conjugate addition/nucleophilic acyl substitution using samarium(II) iodide is reported. The reaction relies on the reagent's unique ability to mediate both radical and anionic pathways, which are likely integral to the mechanism of this transformation. The tricyclic hemiacetal product was formed in good yield, with excellent diastereoselectivity, and its structure was verified by X-ray crystallographic analysis.

Setup and validation of a reliable docking protocol for the development of neuroprotective agents by targeting the sigma-1 receptor (S1R)

Sigma-1 receptor (S1R) is a promising molecular target for the development of novel effective therapies against neurodegenerative diseases. To speed up the discovery of new S1R modulators, herein we report the development of a reliable in silico protocol suitable to predict the affinity of small molecules against S1R. The docking method was validated by comparing the computational calculated Ki values of a test set of new aryl-aminoalkyl-ketone with experimental determined binding affinity. The druggability profile of the new compounds, with particular reference to the ability to cross the blood–brain barrier (BBB) was further predicted in silico. Moreover, the selectivity over Sigma-2 receptor (S2R) and N-methyl-d-aspartate (NMDA) receptor, another protein involved in neurodegeneration, was evaluated. 1-([1,1′-biphenyl]-4-yl)-4-(piperidin-1-yl)butan-1-one (12) performed as the best compound and was further investigated for acetylcholinesterase (AchE) inhibitor activity and determination of antioxidant activity mediated by aquaporins (AQPs). With a good affinity against both S1R and NMDA receptor, good selectivity over S2R and favorable BBB penetration potential together with its AChE inhibitory activity and its ability to exert antioxidant effects through modulation of AQPs, 12 represents a viable candidate for further development as a neuroprotective agent.

Pyrazolopyrimidine macrocyclic derivative and application thereof

The invention relates to a novel pyrazolopyrimidine macrocyclic derivative as well as a preparation method and application thereof in medicines. Specifically, the invention relates to a new pyrazolopyrimidine macrocyclic derivative as shown in a general formula (I), a preparation method thereof, and application of the pyrazolopyrimidine macrocyclic derivative or a pharmaceutical composition containing the derivative as a therapeutic agent, especially as a tropomyosin-related kinase (TRK) inhibitor, in treatment or prevention of TRK-mediated related diseases such as tumors. Substituents (R1, R2) and groups (X) in the general formula (I) are as defined in the description.

MACROCYCLE CONTAINING AMINOPYRAZOLE AND PYRIMIDINE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (I), a pharmaceutical composition thereof, and a use thereof in inhibiting tropomyosin receptor kinase (Trk) activity and in treating diseases in mammals that are mediated by Trk.

AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR

Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.

Synthesis of 2-alkyl-2-boryl-substituted-tetrahydrofurans: Via copper(i)-catalysed borylative cyclization of aliphatic ketones

A new method was developed for synthesizing 2-alkyl-2-boryl-tetrahydrofuran derivatives from aliphatic ketones using a copper(i)/N-heterocyclic carbene complex catalyst. This reaction presumably proceeds through the nucleophilic addition of a borylcopper(i) intermediate to ketone, followed by intramolecular substitution of the resulting alkoxide for the halide leaving group. The new borylation products, 2-alkyl-2-boryl-tetrahydrofuran derivatives with a condensed structure around the C-B bond, cannot be synthesized by other methods.

Identification of dual Sigma1 receptor modulators/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents

In this manuscript we report on the design, synthesis and evaluation of dual Sigma 1 Receptor (S1R) modulators/Acetylcholinesterase (AChE) inhibitors endowed with antioxidant and neurotrophic properties, potentially able to counteract neurodegeneration. The compounds based on arylalkylaminoketone scaffold integrate the pharmacophoric elements of RRC-33, a S1R modulator developed by us, donepezil, a well-known AChE inhibitor, and curcumin, a natural antioxidant compound with neuroprotective properties. A small library of compounds was synthesized and preliminary in vitro screening performed. Some compounds showed good S1R binding affinity, selectivity towards S2R and N-Methyl-D-Aspartate (NMDA) receptor, AChE relevant inhibiting activity and are potentially able to bypass the BBB, as predicted by the in silico study. For the hits 10 and 20, the antioxidant profile was assessed in SH-SY5Y human neuroblastoma cell lines by evaluating their protective effect against H2O2 cytotoxicity and reactive oxygen species (ROS) production. Tested compounds resulted effective in decreasing ROS production, thus ameliorating the cellular survival. Moreover, compounds 10 and 20 showed to be effective in promoting the neurite elongation of Dorsal Root Ganglia (DRG), thus demonstrating a promising neurotrophic activity. Of note, the tested compounds did not show any cytotoxic effect at the concentration assayed. Relying on these encouraging results, both compounds will undergo a structure optimization program for the development of therapeutic candidates for neurodegenerative diseases treatment.

Neurotrophic factor tyrosine kinase receptor inhibitor

The invention provides a neurotrophic factor tyrosine kinase receptor inhibitor. The tyrosine kinase receptor inhibitor provided by the invention has a tricyclic parent core structure, can inhibit theactivity of Trk kinase and can be used for treating mammalian diseases mediated by the Trk kinase.

2 R - (2, 5 - difluorophenyl) pyrrolidine hydrochloride preparation method

The invention discloses a method for preparing 2R-(2, 5-difluorophenyl) pyrrolidine hydrochloride. The method comprises the following steps: (a) reacting a compound (1) with the N, O-dimethyl hydroxylamine hydrochloride to obtain a compound (2); (b) react

Pd(II)-catalyzed aerobic intermolecular 1,4-diamination of conjugated dienes: A regioselective [4+4] annulation for the construction of medium-ring 1,6-benzodiazocine derivatives

The first metal-catalyzed oxidative intermolecular 1,4-diamination of conjugated dienes has been developed. A series of medium ring compounds were constructed via palladium-catalyzed intermolecular [4+4] annulations. Oxygen was successfully used as an oxidant instead of the existing stoichiometric metals or hypervalent iodine reagents. 20 examples are reported, and good yields and regioselectivities could be obtained for the majority of diamines and conjugated diene substrates.